rethinkTHC Search
Menu
Study breakdown

How Synthetic Cannabinoids Differ From Natural Cannabis: Stronger Effects, Greater Risks

ReviewModerate evidence
The takeaway

Synthetic cannabinoids produce more intense desired and adverse effects than cannabis because they are full receptor agonists with higher binding affinity, with neurological and cardiovascular complications that can be severe.

Read this if you want to understand the scientific reason why synthetic cannabinoids are more dangerous than marijuana.

Synthetic cannabinoids are full receptor agonists; THC is only a partial agonist

What the researchers found

This review provided a state-of-the-art overview of both natural and synthetic cannabinoids, explaining why synthetic versions produce more extreme effects.

The key pharmacological difference: THC is a partial agonist at CB1 receptors (it activates them partially), while most synthetic cannabinoids are full agonists (they activate receptors to their maximum). Combined with higher receptor binding affinity, this explains why synthetic cannabinoid effects are more intense across the board, both desired effects and side effects.

Neurological and cardiovascular complications are the most commonly reported adverse effects after synthetic cannabinoid poisoning. While most cases respond to conventional supportive care, severe outcomes including death occur in a minority of cases, predominantly with synthetic cannabinoids rather than natural cannabis.

The review also highlighted the endocannabinoid system's involvement in multiple neurotransmission pathways, explaining the broad range of both therapeutic and adverse effects of cannabinoid compounds.

Why it matters

Understanding the pharmacological basis for why synthetic cannabinoids are more dangerous than cannabis is essential for clinicians treating poisoning cases and for public health messaging targeting users who may assume synthetic products are similar to natural cannabis.

The numbers in context

The review notes neurological and cardiovascular effects as the primary adverse outcomes, with severe cases mainly occurring with synthetic rather than natural cannabinoids.

How the study worked

Review article synthesizing current knowledge on the pharmacology, effects, and risks of natural and synthetic cannabinoids, with emphasis on the receptor-level differences that explain their distinct clinical profiles.

What this study cannot tell us

Narrative review without systematic search methodology. The rapidly evolving landscape of synthetic cannabinoids means any review is quickly outdated. Case severity data is largely drawn from case reports and poison center data rather than controlled studies.

How to read the evidence

Review synthesizing pharmacological and clinical evidence. Moderate because it draws on established receptor pharmacology and clinical case data.

When this study was published

Published in 2017.

The bigger picture

The partial versus full agonist distinction is crucial. THC has a built-in safety ceiling because it can only partially activate CB1 receptors. Synthetic cannabinoids lack this ceiling, which means there is no pharmacological limit on how strongly they stimulate the receptor system, explaining the overdose risk that does not exist with natural cannabis.

Questions still open

  • Are there structural features of synthetic cannabinoids that predict severity of adverse effects? Would legal cannabis access reduce synthetic cannabinoid use and associated harms? Could partial agonist synthetic cannabinoids be designed for therapeutic use?

Common questions

Why are synthetic cannabinoids stronger than marijuana?
THC partially activates CB1 receptors (partial agonist), creating a natural ceiling on how strong the effect can be. Synthetic cannabinoids fully activate these receptors (full agonists) with no ceiling, and often bind with higher affinity, producing more intense effects.
What are the main dangers of synthetic cannabinoids?
Neurological complications (seizures, psychosis, altered consciousness) and cardiovascular effects are the most commonly reported serious adverse events. While most cases respond to supportive care, severe outcomes including death are possible.

Read the original research

Focus on cannabinoids and synthetic cannabinoids.

Clinical pharmacology and therapeutics, 101(2), 220-229

Citation

Le Boisselier, R; Alexandre, J; Lelong-Boulouard, V; Debruyne, D. (2017). Focus on cannabinoids and synthetic cannabinoids.. Clinical pharmacology and therapeutics, 101(2), 220-229. https://doi.org/10.1002/cpt.563

Explore the wider topic